On March 27, the inauguration ceremony for SINOPHARM (Xiong'an) Co., Ltd. and a conference on the development of the pharmaceutical industry under the guidance of the Healthy China initiative were held in the Xiong'an New Area. This marks a significant step by China National Pharmaceutical Group Co., Ltd. (SINOPHARM) to deepen its involvement in the construction of the new area, playing a vital role in enhancing the pharmaceutical and health industry's capacity and improving the city's comprehensive service functions.
SINOPHARM is a leading global enterprise in the pharmaceutical and health sector, with a comprehensive industrial chain advantage covering pharmaceutical R&D, industrial manufacturing, logistics distribution, and retail chains. As the group's core pharmaceutical commercial platform, SINOPHARM (Xiong'an) Co., Ltd. possesses a nationwide pharmaceutical supply chain network and internationally advanced logistics capabilities. Establishing a presence in Xiong'an is a key move by SINOPHARM to respond to national strategies and integrate into the millennium plan, as well as an important practice to optimize the regional pharmaceutical supply chain layout and enhance the new area's healthcare service capabilities.
With the proactive support and precise coordination of the Xiong'an Pilot Free Trade Zone Management Committee, SINOPHARM (Xiong'an) Co., Ltd. completed its registration at the Xiong'an Free Trade Building on January 19. The company will continue to ensure the supply of pharmaceuticals and medical equipment to medical institutions at all levels in the new area. It will leverage the advantages of a central state-owned enterprise in serving relocated hospitals and industrial clustering, actively explore pilot models for the introduction of innovative medicines and devices, internet-plus healthcare, and smart pharmacies, and build a high-standard, full-chain industrial platform to jointly create a new ecosystem for the coordinated development of the pharmaceutical and health industry with Xiong'an.
Comments